Drugs / HLX15-IV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06895512 | Apr 2025 → Jul 2027 expected | plasma cell myeloma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX15-IV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895512 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-CD38 human monoclonal antibody injection” NCT06895512 ↗ |
| Target | CD38 | “recombinant anti-CD38 human monoclonal antibody injection” NCT06895512 ↗ |